BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 29974231)

  • 1. Multicenter phase 1/2 study of forodesine in patients with relapsed peripheral T cell lymphoma.
    Maruyama D; Tsukasaki K; Uchida T; Maeda Y; Shibayama H; Nagai H; Kurosawa M; Suehiro Y; Hatake K; Ando K; Yoshida I; Hidaka M; Murayama T; Okitsu Y; Tsukamoto N; Taniwaki M; Suzumiya J; Tamura K; Yamauchi T; Ueda R; Tobinai K
    Ann Hematol; 2019 Jan; 98(1):131-142. PubMed ID: 29974231
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase I study of BCX1777 (forodesine) in patients with relapsed or refractory peripheral T/natural killer-cell malignancies.
    Ogura M; Tsukasaki K; Nagai H; Uchida T; Oyama T; Suzuki T; Taguchi J; Maruyama D; Hotta T; Tobinai K
    Cancer Sci; 2012 Jul; 103(7):1290-5. PubMed ID: 22448814
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Final results of a multicenter phase II study of the purine nucleoside phosphorylase (PNP) inhibitor forodesine in patients with advanced cutaneous T-cell lymphomas (CTCL) (Mycosis fungoides and Sézary syndrome).
    Dummer R; Duvic M; Scarisbrick J; Olsen EA; Rozati S; Eggmann N; Goldinger SM; Hutchinson K; Geskin L; Illidge TM; Giuliano E; Elder J; Kim YH
    Ann Oncol; 2014 Sep; 25(9):1807-1812. PubMed ID: 24948692
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Forodesine in the treatment of cutaneous T-cell lymphoma.
    Lewis DJ; Duvic M
    Expert Opin Investig Drugs; 2017 Jun; 26(6):771-775. PubMed ID: 28447489
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Forodesine in the treatment of relapsed/refractory peripheral T-cell lymphoma: an evidence-based review.
    Makita S; Maeshima AM; Maruyama D; Izutsu K; Tobinai K
    Onco Targets Ther; 2018; 11():2287-2293. PubMed ID: 29719411
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase 2 and pharmacodynamic study of oral forodesine in patients with advanced, fludarabine-treated chronic lymphocytic leukemia.
    Balakrishnan K; Verma D; O'Brien S; Kilpatrick JM; Chen Y; Tyler BF; Bickel S; Bantia S; Keating MJ; Kantarjian H; Gandhi V; Ravandi F
    Blood; 2010 Aug; 116(6):886-92. PubMed ID: 20427701
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Belinostat in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma: Results of the Pivotal Phase II BELIEF (CLN-19) Study.
    O'Connor OA; Horwitz S; Masszi T; Van Hoof A; Brown P; Doorduijn J; Hess G; Jurczak W; Knoblauch P; Chawla S; Bhat G; Choi MR; Walewski J; Savage K; Foss F; Allen LF; Shustov A
    J Clin Oncol; 2015 Aug; 33(23):2492-9. PubMed ID: 26101246
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Results from a prospective, open-label, phase II trial of bendamustine in refractory or relapsed T-cell lymphomas: the BENTLY trial.
    Damaj G; Gressin R; Bouabdallah K; Cartron G; Choufi B; Gyan E; Banos A; Jaccard A; Park S; Tournilhac O; Schiano-de Collela JM; Voillat L; Joly B; Le Gouill S; Saad A; Cony-Makhoul P; Vilque JP; Sanhes L; Schmidt-Tanguy A; Bubenheim M; Houot R; Diouf M; Marolleau JP; Béné MC; Martin A; Lamy T
    J Clin Oncol; 2013 Jan; 31(1):104-10. PubMed ID: 23109692
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Romidepsin in Japanese patients with relapsed or refractory peripheral T-cell lymphoma: a phase I/II and pharmacokinetics study.
    Maruyama D; Tobinai K; Ogura M; Uchida T; Hatake K; Taniwaki M; Ando K; Tsukasaki K; Ishida T; Kobayashi N; Ishizawa K; Tatsumi Y; Kato K; Kiguchi T; Ikezoe T; Laille E; Ro T; Tamakoshi H; Sakurai S; Ohtsu T
    Int J Hematol; 2017 Nov; 106(5):655-665. PubMed ID: 28664499
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Final report of a phase 2 clinical trial of lenalidomide monotherapy for patients with T-cell lymphoma.
    Toumishey E; Prasad A; Dueck G; Chua N; Finch D; Johnston J; van der Jagt R; Stewart D; White D; Belch A; Reiman T
    Cancer; 2015 Mar; 121(5):716-23. PubMed ID: 25355245
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Multicenter phase II study of mogamulizumab (KW-0761), a defucosylated anti-cc chemokine receptor 4 antibody, in patients with relapsed peripheral T-cell lymphoma and cutaneous T-cell lymphoma.
    Ogura M; Ishida T; Hatake K; Taniwaki M; Ando K; Tobinai K; Fujimoto K; Yamamoto K; Miyamoto T; Uike N; Tanimoto M; Tsukasaki K; Ishizawa K; Suzumiya J; Inagaki H; Tamura K; Akinaga S; Tomonaga M; Ueda R
    J Clin Oncol; 2014 Apr; 32(11):1157-63. PubMed ID: 24616310
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Forodesine (BCX-1777, Immucillin H)--a new purine nucleoside analogue: mechanism of action and potential clinical application.
    Korycka A; Błoński JZ; Robak T
    Mini Rev Med Chem; 2007 Sep; 7(9):976-83. PubMed ID: 17897085
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Drug evaluation: forodesine - PNP inhibitor for the treatment of leukemia, lymphoma and solid tumor.
    Galmarini CM
    IDrugs; 2006 Oct; 9(10):712-22. PubMed ID: 17016779
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Three new drugs for acute lymphoblastic leukemia: nelarabine, clofarabine, and forodesine.
    Larson RA
    Semin Oncol; 2007 Dec; 34(6 Suppl 5):S13-20. PubMed ID: 18086342
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Multicenter Phase II Study of Lenalidomide in Relapsed or Recurrent Adult T-Cell Leukemia/Lymphoma: ATLL-002.
    Ishida T; Fujiwara H; Nosaka K; Taira N; Abe Y; Imaizumi Y; Moriuchi Y; Jo T; Ishizawa K; Tobinai K; Tsukasaki K; Ito S; Yoshimitsu M; Otsuka M; Ogura M; Midorikawa S; Ruiz W; Ohtsu T
    J Clin Oncol; 2016 Dec; 34(34):4086-4093. PubMed ID: 27621400
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A proof-of-principle pharmacokinetic, pharmacodynamic, and clinical study with purine nucleoside phosphorylase inhibitor immucillin-H (BCX-1777, forodesine).
    Gandhi V; Kilpatrick JM; Plunkett W; Ayres M; Harman L; Du M; Bantia S; Davisson J; Wierda WG; Faderl S; Kantarjian H; Thomas D
    Blood; 2005 Dec; 106(13):4253-60. PubMed ID: 16131572
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bendamustine for the treatment of relapsed or refractory peripheral T cell lymphomas: A French retrospective multicenter study.
    Reboursiere E; Le Bras F; Herbaux C; Gyan E; Clavert A; Morschhauser F; Malak S; Sibon D; Broussais F; Braun T; Fornecker LM; Garidi R; Tricot S; Houot R; Joly B; Abarah W; Choufi B; Pham AD; Gac AC; Fruchart C; Marin E; Safar V; Parcelier A; Maisonneuve H; Bachy E; Cartron G; Jaccard A; Tournilhac O; Rossi C; Schirmer L; Martignoles JA; Gaulard P; Tilly H; Damaj G;
    Oncotarget; 2016 Dec; 7(51):85573-85583. PubMed ID: 27458168
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Modified ESHAP regimen for relapsed/refractory T cell lymphoma: a retrospective analysis.
    Kogure Y; Yoshimi A; Ueda K; Nannya Y; Ichikawa M; Nakamura F; Kurokawa M
    Ann Hematol; 2015 Jun; 94(6):989-94. PubMed ID: 25687839
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A phase 2, multicentre, single-arm, open-label study to evaluate the safety and efficacy of single-agent lenalidomide (Revlimid) in subjects with relapsed or refractory peripheral T-cell non-Hodgkin lymphoma: the EXPECT trial.
    Morschhauser F; Fitoussi O; Haioun C; Thieblemont C; Quach H; Delarue R; Glaisner S; Gabarre J; Bosly A; Lister J; Li J; Coiffier B
    Eur J Cancer; 2013 Sep; 49(13):2869-76. PubMed ID: 23731832
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lenalidomide in relapsed adult T-cell leukaemia-lymphoma or peripheral T-cell lymphoma (ATLL-001): a phase 1, multicentre, dose-escalation study.
    Ogura M; Imaizumi Y; Uike N; Asou N; Utsunomiya A; Uchida T; Aoki T; Tsukasaki K; Taguchi J; Choi I; Maruyama D; Nosaka K; Chen N; Midorikawa S; Ohtsu T; Tobinai K
    Lancet Haematol; 2016 Mar; 3(3):e107-18. PubMed ID: 26947199
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.